This Clinical Industrial partnership does not result in any immediate revenue lines for OSX, I will add this as part of R&D. While the company might have some niche products, I doubt the business acumen of those who run the company. To let the stock slide to its present level without evoking any response from the management shows lack of intent and sensitivity to shareholder interest.
